Seven Eight Capital’s Arcus Biosciences RCUS Stock Holding History

Seven Eight Capital’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-16,265	Closed	-$292K	–	797
2023 Q3	$292K	Buy	+16,265	New	+$327K	0.03%	496

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Seven Eight Capital's RCUS Position: Q4 2023 in Review

Seven Eight Capital sold out of Arcus Biosciences (RCUS) in Q4 2023, closing a stake of 16,265 shares — an estimated $292K sold.

Seven Eight Capital first reported a position in RCUS in Q3 2023 and held it in 1 quarter. The position peaked at $292K in Q3 2023. 185 funds tracked by Wall St. Rank hold RCUS as of Q4 2023.

Seven Eight Capital reported no remaining Arcus Biosciences position as of Q4 2023 after selling out during the quarter.
Seven Eight Capital sold 16,265 Arcus Biosciences shares in Q4 2023, an estimated $292K.
Seven Eight Capital first reported a position in Arcus Biosciences in Q3 2023 and held it in 1 quarter.
Seven Eight Capital's Arcus Biosciences position peaked at $292K in Q3 2023.
185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2023.

Based on Seven Eight Capital's 13F filing for Q4 2023, filed 13 Feb 2024.